Table 1.
Clinical trials using epigenetic therapy.
| Trial | HDAC class targeted | Disease | Clinical trial phase | Status | Protocol ID |
|---|---|---|---|---|---|
| Vorinostat, isotretinoin, carboplatin | I, II | Recurrent GBM | I, II | Active | NCT00555399 |
| Vorinostat, bevacizumab, temozolomide | I, II | Recurrent GBM | I, II | Active | NCT00939991 |
| Vorinostat, borezomib | I, II | Recurrent GBM | II | Active | NCT00641706 |
| Vorinostat, temozolomide | I, II | Malignant gliomas | I | Active | NCT00268385 |
| Vorinostat, temozolomide, radiation | I, II | GBM | I, II | Temporarily closed | NCT00731731 |
| Vorinostat | I, II | Progressive or recurrent GBM | II | Closed | NCT00238303 |
| Vorinostat, bevacizumab, irinotecan | I, II | Recurrent GBM | I | Closed | NCT00762255 |
| Panobinostat, bevacizumab | I, II | Recurrent high-grade glioma | I, II | Active | NCT00859222 |
| Panobinostat | I, II | Malignant brain tumor | II | Active | NCT00848523 |
| Valproic acid, temozolomide, radiation | I, IIa | GBM | II | Active | NCT00313664 |
| Valproic acid | I, IIa | High-grade glioma in children | II | Active | NCT00879437 |
| Valproic acid, etoposide | I, IIa | Neuronal tumors & brain metastases | I | Active | NCT00513162 |
| Valproic acid | I, IIa | Recurrent or refractory CNS tumors in children | I | Closed | NCT00107458 |
| Romidepsin | I, II, IV | Recurrent high-grade glioma | I, II | Closed | NCT00085540 |
GBM: Glioblastoma multiforme; HDAC: Histone deacetylases.